← All themes

GLP-1 & Obesity

GLP-1 medicines treat obesity and diabetes, and have grown into one of the largest drug categories ever launched. Their reach extends past medicine, because a change in how much people eat moves whole consumer industries.

92 stocks

Obesity Second-Order Effects

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Pfizer PFE $169B	3,044	-61	-2%	$145B
2	2 Eli Lilly LLY $1.13T	2,815	+201	+8%	$367B
3	3 Amgen AMGN $238B	2,391	-44	-2%	$90.1B
4	4 Becton Dickinson BDX $52.5B	1,577	+52	+3%	$67.2B
5	5 McKesson MCK $116B	1,320	+55	+4%	$49.2B
6	6 Novo Nordisk NVO $174B	1,196	+51	+4%	$23.2B
7	7 Regeneron Pharmaceuticals REGN $82.4B	1,164	-27	-2%	$66.2B
8	8 AstraZeneca AZN $260B	1,091	+36	+3%	$35.4B
9	9 Conagra Brands CAG $6.82B	864	-26	-3%	$13.8B
10	10 Lamb Weston LW $7.47B	781	+39	+5%	$14.4B
11	11 West Pharmaceutical WST $26.9B	734	+39	+6%	$26B
12	12 ResMed RMD $33.9B	730	+53	+8%	$20.8B
13	13 DaVita DVA $11.9B	471	+32	+7%	$7.86B
14	14 DELISTED CATALENT, INC. CTLT	441	-85	-16%	$8.72B
15	15 Teva Pharmaceutical Industries Limited TEVA $48.2B	428	-10	-2%	$3.74B
16	16 Inspire Medical Systems INSP $2B	407	+34	+9%	$9.11B
17	17 Embecta EMBC $369M	399	-34	-8%	$1.16B
18	18 BellRing Brands BRBR $1.04B	311	0	0%	$4.6B
19	TWNK 19 DELISTED Hostess Brands, Inc. Class A Common Stock TWNK	273	+9	+3%	$3.46B
20	20 Amphastar Pharmaceuticals AMPH $1.13B	245	+27	+12%	$1.8B
21	21 Medifast MED $135M	236	-31	-12%	$892M
22	22 Accendra Health ACH $21.2M	230	+13	+6%	$1.44B
23	23 Opko Health OPK $1.16B	229	+2	+0.9%	$376M
24	24 Madrigal Pharmaceuticals MDGL $10.7B	208	-15	-7%	$3.43B
25	25 Dr. Reddy's Laboratories RDY $10.8B	194	+4	+2%	$1.31B